iShares Evolved U.S. Innovative Healthcare ETF (IEIH)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
iShares Evolved U.S. Innovative Healthcare ETF (IEIH) with AI Score 44/100 (Weak). iShares Evolved U. S. Innovative Healthcare ETF (IEIH) focuses on U. Market cap: 0, Sector: Financial services.
Last analyzed: Mar 16, 2026iShares Evolved U.S. Innovative Healthcare ETF (IEIH) Financial Services Profile
iShares Evolved U.S. Innovative Healthcare ETF (IEIH) provides targeted exposure to U.S. listed innovative healthcare companies, including pharmaceutical and biotechnology firms. With a focused, non-diversified approach, IEIH seeks to mirror the economic performance of the innovative healthcare sector, offering investors a specialized investment vehicle.
Investment Thesis
IEIH offers targeted exposure to the innovative healthcare sector, specifically U.S.-listed pharmaceutical and biotechnology companies. With a beta of 0.58, IEIH demonstrates lower volatility compared to the broader market, potentially offering a more stable investment within the healthcare sector. The fund's non-diversified nature allows for concentrated exposure to its target sector, potentially amplifying returns if the innovative healthcare industry performs well. However, the absence of dividend payments may deter income-focused investors. Key value drivers include the growth and innovation within the pharmaceutical and biotechnology industries. The fund's performance is closely tied to the success of its constituent companies and the overall health of the healthcare sector.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap: $0.04B, indicating a relatively small fund size.
- Beta: 0.58, suggesting lower volatility compared to the broader market.
- Dividend Yield: None, indicating no income generation for investors.
- Focus on U.S. listed pharmaceutical and biotechnology companies, providing targeted exposure to the innovative healthcare sector.
- Non-diversified structure, allowing for concentrated investment in the innovative healthcare sector.
Competitors & Peers
Strengths
- Targeted exposure to the innovative healthcare sector.
- Low expense ratio.
- Established brand recognition of iShares.
- Potential for high growth in the healthcare sector.
Weaknesses
- Non-diversified structure, leading to higher volatility.
- Absence of dividend payments.
- Small market capitalization.
- Reliance on the performance of a specific sector.
Catalysts
- Upcoming: Positive clinical trial results for pharmaceutical and biotechnology companies within the fund's portfolio.
- Ongoing: Increased mergers and acquisitions activity in the healthcare sector.
- Ongoing: Favorable regulatory changes supporting healthcare innovation.
- Ongoing: Technological advancements driving growth in the healthcare industry.
Risks
- Potential: Regulatory changes impacting the pharmaceutical and biotechnology industries.
- Potential: Clinical trial failures for companies within the fund's portfolio.
- Potential: Economic downturns affecting healthcare spending.
- Ongoing: Competition from generic drugs and biosimilars.
- Ongoing: Market volatility affecting the value of the fund's holdings.
Growth Opportunities
- Increased Investment in Healthcare Innovation: The ongoing investment in healthcare innovation, driven by factors such as aging populations and technological advancements, presents a significant growth opportunity for IEIH. As pharmaceutical and biotechnology companies develop new treatments and technologies, the fund stands to benefit from the potential appreciation in the value of its holdings. The global biotechnology market is projected to reach $1.03 trillion by 2028, growing at a CAGR of 12.3%.
- Aging Population and Increased Healthcare Spending: The aging global population is driving increased demand for healthcare services and products, creating a favorable environment for the innovative healthcare sector. As the population ages, the need for new and improved treatments for age-related diseases will continue to grow, benefiting companies within IEIH's portfolio. Global healthcare expenditure is projected to reach $10 trillion by 2022.
- Technological Advancements in Healthcare: Technological advancements, such as gene editing, artificial intelligence, and personalized medicine, are transforming the healthcare industry. These advancements are creating new opportunities for pharmaceutical and biotechnology companies to develop innovative treatments and therapies, driving growth within the sector. The global artificial intelligence in healthcare market is projected to reach $34 billion by 2025.
- Expansion of Emerging Markets: The growth of emerging markets and increasing access to healthcare in these regions presents a significant growth opportunity for the innovative healthcare sector. As emerging markets develop, the demand for advanced medical treatments and technologies will increase, benefiting companies within IEIH's portfolio. The pharmaceutical market in emerging economies is expected to grow at a faster rate than developed markets.
- Mergers and Acquisitions in the Healthcare Industry: Mergers and acquisitions (M&A) activity within the healthcare industry can create value for shareholders and drive growth for companies within IEIH's portfolio. M&A transactions can lead to increased efficiency, expanded market share, and access to new technologies. The healthcare M&A market is expected to remain active in the coming years, driven by factors such as consolidation and the desire to acquire innovative technologies.
Opportunities
- Increased investment in healthcare innovation.
- Aging population and increased healthcare spending.
- Technological advancements in healthcare.
- Expansion of emerging markets.
Threats
- Regulatory changes in the healthcare industry.
- Competition from other healthcare ETFs.
- Economic downturns affecting healthcare spending.
- Patent expirations and generic competition.
Competitive Advantages
- Established brand recognition of iShares as a leading ETF provider.
- Targeted exposure to the innovative healthcare sector.
- Low expense ratio compared to actively managed funds.
About IEIH
The iShares Evolved U.S. Innovative Healthcare ETF (IEIH) is designed to provide investors with targeted exposure to the U.S. innovative healthcare sector. IEIH primarily invests in the common stock of large-, mid-, and small-capitalization pharmaceutical and biotechnology companies listed in the U.S. The ETF operates under the principle of investing at least 80% of its net assets in companies that fall into the Innovative Healthcare Evolved Sector. This sector is defined by companies exhibiting economic characteristics historically correlated with traditional pharmaceutical and biotechnology firms. IEIH's investment strategy focuses on capturing the performance of innovative healthcare companies, offering a specialized investment vehicle for those seeking exposure to this specific segment of the market. As a non-diversified fund, IEIH concentrates its investments, which may lead to higher volatility compared to more diversified ETFs. The fund's objective is to mirror the economic performance of the innovative healthcare sector, providing investors with a focused investment tool.
What They Do
- Invests primarily in U.S. listed common stock.
- Targets large-, mid-, and small-capitalization pharmaceutical and biotechnology companies.
- Focuses on companies within the Innovative Healthcare Evolved Sector.
- Aims to mirror the economic characteristics of traditional pharmaceutical and biotechnology companies.
- Operates as a non-diversified fund.
- Seeks to provide targeted exposure to the U.S. innovative healthcare sector.
Business Model
- The fund generates revenue through investment in U.S. listed innovative healthcare companies.
- The fund's performance is tied to the success of its constituent companies and the overall health of the healthcare sector.
- Expense ratio charged to investors to cover operational costs.
Industry Context
The asset management industry is characterized by a diverse range of investment vehicles, including ETFs like IEIH. The ETF market has experienced significant growth, driven by increasing investor demand for low-cost, passively managed investment options. IEIH operates within the innovative healthcare segment, competing with other specialized ETFs that target specific sectors or investment strategies. The competitive landscape includes both broad-based healthcare ETFs and more narrowly focused funds. IEIH's success depends on its ability to effectively track the performance of the innovative healthcare sector and attract investors seeking targeted exposure to this market.
Key Customers
- Institutional investors seeking targeted exposure to the innovative healthcare sector.
- Retail investors interested in pharmaceutical and biotechnology companies.
- Investors looking for a specialized investment vehicle within the healthcare market.
Financials
Chart & Info
iShares Evolved U.S. Innovative Healthcare ETF (IEIH) stock price: Price data unavailable
Latest News
No recent news available for IEIH.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IEIH.
Price Targets
Wall Street price target analysis for IEIH.
MoonshotScore
What does this score mean?
The MoonshotScore rates IEIH's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
What Investors Ask About iShares Evolved U.S. Innovative Healthcare ETF (IEIH)
What does iShares Evolved U.S. Innovative Healthcare ETF do?
The iShares Evolved U.S. Innovative Healthcare ETF (IEIH) is designed to provide investors with targeted exposure to the U.S. innovative healthcare sector. It invests primarily in U.S.-listed common stocks of large-, mid-, and small-capitalization pharmaceutical and biotechnology companies. The ETF aims to capture the economic characteristics of companies traditionally defined as pharmaceutical and biotechnology firms, offering a specialized investment vehicle for those seeking exposure to this specific segment of the market. IEIH is a non-diversified fund, concentrating its investments in the innovative healthcare sector.
What do analysts say about IEIH stock?
AI analysis is pending for IEIH. Generally, analysts covering ETFs in the healthcare sector focus on factors such as the fund's expense ratio, tracking error, and exposure to specific sub-sectors within healthcare, such as pharmaceuticals, biotechnology, and medical devices. The performance of IEIH is closely tied to the growth and innovation within the pharmaceutical and biotechnology industries. Investors may want to evaluate the fund's non-diversified nature and the potential for volatility when evaluating its suitability for their portfolios. Further AI analysis will provide more specific insights.
What are the main risks for IEIH?
The main risks for IEIH include regulatory changes impacting the pharmaceutical and biotechnology industries, clinical trial failures for companies within the fund's portfolio, and economic downturns affecting healthcare spending. As a non-diversified fund, IEIH is also subject to higher volatility compared to more diversified ETFs. Competition from generic drugs and biosimilars can also negatively impact the performance of companies within the fund's portfolio. Market volatility and fluctuations in investor sentiment can also affect the value of the fund's holdings.
How sensitive is IEIH to changes in healthcare regulations?
IEIH's performance is significantly influenced by changes in healthcare regulations. New regulations can impact the pricing of pharmaceuticals, the approval process for new drugs, and the overall profitability of healthcare companies. For example, government initiatives aimed at reducing drug prices could negatively affect the revenue and earnings of pharmaceutical companies within IEIH's portfolio. Investors should closely monitor regulatory developments and their potential impact on the innovative healthcare sector and the fund's performance. Any uncertainty or unfavorable regulatory changes can lead to increased volatility and decreased investor confidence.
How does IEIH compare to other healthcare ETFs?
IEIH distinguishes itself from other healthcare ETFs through its evolved sector focus, targeting companies with economic characteristics similar to traditional pharmaceutical and biotechnology firms, even if they are classified differently. While some healthcare ETFs offer broad exposure to the entire healthcare sector, IEIH provides a more concentrated investment in innovative healthcare companies. This targeted approach can lead to higher potential returns if the innovative healthcare sector performs well, but it also carries a higher level of risk due to the fund's non-diversified nature. Investors should compare IEIH's investment strategy, expense ratio, and historical performance to other healthcare ETFs to determine its suitability for their investment goals.
What are the key factors to evaluate for IEIH?
iShares Evolved U.S. Innovative Healthcare ETF (IEIH) currently holds an AI score of 44/100, indicating low score. Key strength: Targeted exposure to the innovative healthcare sector.. Primary risk to monitor: Potential: Regulatory changes impacting the pharmaceutical and biotechnology industries.. This is not financial advice.
How frequently does IEIH data refresh on this page?
IEIH prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven IEIH's recent stock price performance?
Recent price movement in iShares Evolved U.S. Innovative Healthcare ETF (IEIH) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Targeted exposure to the innovative healthcare sector.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for IEIH.
- The fund is non-diversified, which may lead to higher volatility.
- The fund's performance is tied to the success of its constituent companies and the overall health of the healthcare sector.